A5016873533- Sports injuries and prevention
- Potassium and Related Disorders
- Ion Transport and Channel Regulation
- Allergic Rhinitis and Sensitization
- Food Allergy and Anaphylaxis Research
- Bone fractures and treatments
- Tendon Structure and Treatment
- Shoulder Injury and Treatment
- Neurotransmitter Receptor Influence on Behavior
- Receptor Mechanisms and Signaling
- Foot and Ankle Surgery
- Electrolyte and hormonal disorders
- Asthma and respiratory diseases
- Neuroscience and Neuropharmacology Research
University of Louisville
2020-2021
Eli Lilly (United States)
2017
DETQ, an allosteric potentiator of the dopamine D1 receptor, was tested in therapeutic models that were known to respond agonists. Because a species difference affinity for all rodent experiments used transgenic mice expressing human receptor (hD1 mice). When given alone, DETQ reversed locomotor depression caused by low dose reserpine. also acted synergistically with L-DOPA reverse strong hypokinesia seen higher These results indicate potential as both monotherapy and adjunct treatment...
Angiotensin-converting enzyme (ACE) inhibitors are a class of medications that have formed the backbone hypertension management. Of these medications, lisinopril is one most commonly used. While known serious side effects all ACE include angioedema and hyperkalemia, inhibitor-associated hyponatremia has been rarely reported. We present patient with severe associated use discuss link between inhibitors.
HISTORY: A 15 year-old male cross-country (XC) athlete presented in January 2023 with lateral right ankle pain. He denied any trauma or known mechanism of injury, but reported an increase mileage over the course his XC season. His pain had insidiously started November 2022 while training for indoor track. noted complete resolution after a 2 week break December, symptoms progressed he resumed activity January. numbness tingling foot endorsed weakness due to plantar flexion, inversion, and...